Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease - Trial NCT05513729
Access comprehensive clinical trial information for NCT05513729 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital Xi'an Jiaotong University and is currently Recruiting. The study focuses on Type 2 Diabetes Mellitus With Complication. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
First Affiliated Hospital Xi'an Jiaotong University
Timeline & Enrollment
N/A
Aug 18, 2022
Mar 01, 2024
Primary Outcome
Plasma cholesteryl ester transfer protein(CETP) concentration(ug/mL),The activity of CEPT in pmol/mL/min
Summary
Type 2 diabetes mellitus (T2DM) is always accompanied with nonalcoholic fatty liver disease
 (NAFLD).This prospective study was designed to reveal the potential clinical application and
 underlying mechanisms of canagliflozin in the treatment of type 2 diabetes combined with
 nonalcoholic fatty liver disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05513729
Non-Device Trial